This website uses cookies primarily for visitor analytics. Certain pages will ask you to fill in contact details to receive additional information. On these pages you have the option of having the site log your details for future visits. Indicating you want the site to remember your details will place a cookie on your device. To view our full cookie policy, please click here. You can also view it at any time by going to our Contact Us page.

Hypalon crisis fears allayed

26 August 2009

BM Polyco, one of the UK’s leading suppliers of hand protection, has been instrumental in easing the potentially serious effects of Du Pont’s decision to close its only Hypalon manufacturing plant in Beaumont, United States.

Hypalon crisis fears allayed
Hypalon crisis fears allayed

Hypalon, currently made solely by Du Pont, is used to make the industry- standard containment gloves and gauntlets for applications in the nuclear and pharmaceutical markets. Given that the validation and approval processes for these essential items are lengthy, the closure plans posed a real danger for the respective industries.

The planned closure of the plant was brought about by the current economic climate. Hypalon (CSM- Chlorosulphonated Polyethylene) as a material has several specialist niche applications, however its primary market has been the Automotive sector. As an indirect consequence of the intense global downturn, the Texas based production plant was rendered financially unviable.

However, due to BM Polyco and French glove manufacturer Piercan lobbying Du Pont, along with recent successful discussions at the American Glovebox Society’s annual conference, the original plans for closure of the plant in June have been delayed. Furthermore, there is promise that the plant will continue to run into the first quarter of 2010 should there be sufficient demand.            
Major users, such as Sellafield Sites and AWE along with leading glove manufacturers BM Polyco and Piercan worked together with Du Pont to allay initial fears and draw up a plan to ensure adequate production quantities are made available to allow time for alternatives to be sought.
BM Polyco has already identified potential technologies which could offer an alternative to Hypalon, and has commenced an intensive programme to develop new products for a range of markets including nuclear and pharmaceutical.

Contact Details and Archive...

Print this page | E-mail this page